Kowa Invests $8.4 Million In Scotland
Kowa Company, the Japanese pharmaceutical firm, is to invest L5 million($8.4 million) in a three-year project at two Scottish universities to develop a new generation of drugs to combat a wide range of inflammatory conditions.
Kowa has agreed the terms of the deal with the Scottish Biomedical Foundation, which secured the investment for the universities of Strathclyde and Edinburgh. Research will primarily focus on the development of a range of advanced products for the treatment of complaints such as psoriasis, and Crohn's disease.
Kowa is the latest Japanese drugs company to invest in Scotland, joining Yoshitomi which is establishing a neuroscience research institute in Glasgow (Marketletter September 29).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze